Proposed Agenda for 2020 IRLSSG Annual Meeting

Program Committee: Denise Sharon (USA), Aaro Salminen (Germany)

Target audience:
  1. Sleep specialists and internists interested in sleep disorders and in identifying and treating RLS with a more basic understanding of the disorder.
  2. RLS experts and researchers in the field.
  3.  Trainees interested in learning and developing the field.

Please note the program is preliminary and may be modified to fit online format, all speakers and topics are subject to change

 Saturday, August 29th 

Session 1. RLS basic science session (chair: A. Salminen, Germany)

7:00  7:15  An Update on the Genetics of RLS (B. Schormair, Germany)

7:15  7:30     An update on molecular studies of RLS (F. Akcimen,  Canada) 

7:30  7:45     Probing the relationship between BTBD9 and MEIS1 in animal models of RLS (Y. Li, USA)

7:45  8:00     Sleep-related muscle activity is augmented by administration of serum from RLS patients in Btbd9 mutant mice. 
    (S. Chikahisa, Japan)

8:00 - 8:15      PTPRD: Drugging a novel RLS target (G.Uhl, USA)

Session 2. New developments in iron measurement and treatment in RLS (chair: R. Allen, USA)

8:51  8:30 Iron regulation, iron status and relevance to iron treatment (C. J. Earley, USA)  

8:30 – 8:45     The clinical implementation of the quantitative transcranial sonography (Celia Garcia Malo, Spain)

8:45  – 9:00    Intravenous Iron protocol for adolescents (D. Picchietti, USA)

9:15  9:30     Intravenous Ferric Carboxymaltose in children, a single center experience (L. DelRosso, USA)

Session 3. Young investigators (chair: R. Zak / A.S. Walters , USA)

9:30  10:45 up to 5 presentations 

 Sunday, August 30th 

Session 4. RLS and PLMS: clinical aspects and treatment (chair: D. Sharon, USA)

7:00 – 7:30 PLMS update (R. Allen, USA)

7:30 – 7:45 Dopaminergic treatment modulates functional brain connectivity in RLS (A. Stefani, Austria)

7:45 – 8:00 Update on Painful Willis-Ekbom disease: an unbearable and distinct form of restless legs? (E. Karroum, USA)   

8:00 – 8:15 Nearly 25% of RLS Patients Nationally Treated With Dopamine Agonists Are Taking Higher Doses Than The Maximum       Recommended By FDA And Expert Guidelines. (J. Winkelman, USA)

8:15 – 8:30 Testing the adenosine hypothesis:  a double-blind, cross-over, placebo-controlled trial with
dipyridamole  (D. Garcia-Borreguero, Spain)

8:30 – 8:45 Epidural electric spinal stimulation in a severe case of RLS/PLM  (M. Manconi, Switzerland)

Session 5. Cooperative and IRLSSG endorsed projects (chair: J. Winkelman, USA)

8:45 – 9:05  Introduction to EURLSSG and Highlights from the EURLSSG meeting (R. Silvestri, Italy)

9:05 – 9:15 RLS projects by RLS foundation (K. Dzienkowski, USA) 

9:15 – 9:25 Experimental Readouts of Animal Models of Restless Legs Syndrome: Consensus Guidelines (A. Salminen, Germany)

9:25 – 9:35 Diagnostic accuracy of RLS tools (R. Allen, USA)  

9:35 – 9:45 Opioid registry update (J. Winkelman, USA)

9:45 – 9:55 RSD project (L. DelRosso, USA)

9:55 – 10:05  Pediatric Task force (Art Walters, USA)

10:05 – 10:15 Update on AASM TF on Guidelines for treating RLS (A. Walters, USA)

10:15 – 10:25 A Call to Arms--breaking down silos and increasing interagency cooperation (R. Zak, USA)

10:25 – 10:35 Year in review  and future projects discussion (J Winkelman, USA)

10:35-10:45 Business meeting

Powered by Wild Apricot Membership Software